Saliva Test Detects Early Signs of Epilepsy, Parkinson’s & Psychosis

A team of researchers in South Korea has achieved a global first: a technique for the early detection of major neurological disorders – including epilepsy, Parkinson’s disease, and schizophrenia – using only a small sample of saliva. The breakthrough, led by Dr. Seong-Kyu Park of the Bio·Health Materials Research Division at the Korea Institute of Materials Science (KIMS), in collaboration with teams from Korea University and Catholic University of Korea, offers a less invasive and potentially more accessible alternative to current diagnostic methods.

A New Approach to Neurological Diagnosis

Current methods for diagnosing these conditions often rely on expensive and potentially risky procedures like blood tests, PET scans, and cerebrospinal fluid analysis. The new technique, dubbed ‘Galvanic Molecular Entrapment (GME)-SERS platform,’ bypasses these hurdles by directly detecting changes in protein structure within a simple saliva sample.

The GME-SERS platform leverages nanostructures based on copper oxide-gold (Au-CuO). These structures create “hotspots” – areas where the electric field is intensely concentrated, amplifying the Raman signal of molecules by up to one billion times. This amplification allows for the detection of even extremely weak biological signals.

Did You Know? The research findings were published online in ‘Advanced Materials’ (IF=26.8), a journal recognised for its high impact factor, signifying the international recognition of the technology’s innovation and foundational nature.

Understanding Protein Changes

The technique focuses on identifying changes in protein fiber formation. Proteins exist in two primary states: monomers, which are single molecules functioning normally, and fibrils, which are abnormally aggregated fiber-like structures. Fibrils are poorly soluble and toxic, playing a key role in the development of neurodegenerative diseases. The GME-SERS platform can accurately distinguish between these two states, something previously difficult to achieve with existing technologies.

The GME-SERS platform first captures biomolecules, like proteins, on a metal surface. As gold grows, it encapsulates the molecules, positioning them within light-sensitive nanoscale spaces. This allows for the strong detection of even trace amounts of protein without the need for additional markers.

High Accuracy in Early Detection

In a collaborative study with Sung Vincent’s Hospital, the research team analyzed saliva samples from a total of 67 individuals – 44 patients diagnosed with epilepsy, schizophrenia, or Parkinson’s disease, and 23 healthy control subjects. The results demonstrated the technology’s ability to classify these conditions with an accuracy rate exceeding 90%, reaching up to 98% in some cases.

Expert Insight: The focus on ‘protein structure changes’ as a diagnostic indicator, rather than overall protein concentration, represents a significant advancement. This approach targets the fundamental pathological basis of these neurological disorders, offering a more precise and potentially earlier detection method.

According to KIMS’s Dr. Seong-Kyu Park, this development “heralds an era where brain disease status can be ascertained through simple saliva analysis, without the need for expensive PET scans or cerebrospinal fluid tests.” Professor Ho-Sang Jung of Korea University added that the non-invasive and low-cost nature of the technology suggests potential for expansion beyond hospital settings, even into home-based diagnostic devices.

What’s Next?

The research team is now focused on commercializing the technology. Possible next steps include developing a portable Raman sensor-based point-of-care diagnostic device and seeking technology transfer agreements with medical and life science companies. We see likely that further research will be conducted to expand the range of detectable neurological conditions. Analysts expect that if successful, this technology could significantly improve early diagnosis and treatment outcomes for millions affected by these debilitating diseases.

Frequently Asked Questions

What types of neurological disorders can this technology detect?

The technology has been demonstrated to accurately classify epilepsy, schizophrenia, and Parkinson’s disease.

How does this technology differ from existing diagnostic methods?

Unlike current methods that rely on blood tests, PET scans, or cerebrospinal fluid analysis, this technique uses only a saliva sample and focuses on detecting changes in protein structure.

What is the accuracy rate of this diagnostic method?

The technology achieved an accuracy rate of 90% or higher, with a maximum accuracy of 98% in classifying the tested conditions.

Could a simple saliva test one day revolutionize the way we approach neurological disease diagnosis and management?